Agios expects to advance cevidoplenib into Phase 3 development for ITP in the first half of 2028, following completion of additional chemistry, manufacturing, and controls (CMC) development work.

cevidoplenib (SKI-O-703) - Agios Pharmaceuticals

Jul 30, 2026